• News
  • Publications
  • Videos
  • Events
  • About
  • Contact

Volastra Therapeutics Raises $12M in Seed Financing

February 12, 2020

Volastra Therapeutics , a NYC-based biotechnology company developing novel therapies for the treatment of metastatic cancers, raised $12m in funding. The round was led by Polaris Partners with participation from DROIA Oncology Ventures, the Global Health Sciences (GHS) Fund (Quark Venture LP and GF Securities), and ARCH Venture Partners. […]

View Original Source at Volastra Therapeutics Raises $12M in Seed Financing

Weekly Digest

Sign up to receive
weekly updates!

No Spum Guarantee

Cancer Types

  • Bladder cancer (2)
  • bowel cancer (3)
  • Brain cancer (7)
  • Breast cancer (6)
  • cervical cancer (1)
  • colon (1)
  • Colon cancer (14)
  • colorectal cancer (6)
  • Drug development (12)
  • Endometrial cancer (2)
  • Esophageal cancer (3)
  • Gastric cancer (5)
  • Hans Clevers (1)
  • Head and neck cancer (4)
  • Immunotherapy (0)
  • Intestinal cancer (8)
  • intestinal organoids (1)
  • Kidney cancer (3)
  • Leukemia (1)
  • Liver cancer (11)
  • Lung cancer (4)
  • melanoma (1)
  • metastatic cancer (1)
  • Organoid (143)
  • Ovarian cancer (8)
  • Pancreatic cancer (19)
  • Peritoneal cancer (1)
  • Personalized medicine (5)
  • Prostate cancer (7)
  • Rectal cancer (1)
  • solid tumor (1)
  • stem cells (1)

ORG
1-617-547-9443

Monday-Friday: 8 am - 8 pm
Saturday: 8 am - 4:30 pm

  • News
  • Publications
  • Videos
  • Events
  • About Us
  • Contact Us
  • Privacy
  • Terms of Use

© COPYRIGHT 2021 Organoid Research Group. ALL RIGHTS RESERVED.